Please login to the form below

Not currently logged in

Vertex forges ties with gene editing firm CRISPR Therapeutics

Aims to find new treatments for genetic diseases such as cystic fibrosis

Vertex is paying $105m upfront to tap into the gene-editing expertise of CRISPR Therapeutics for the development of up to six product candidates.

The wide-ranging deal - in which Vertex is taking a $30m equity stake in CRISPR and will pay up to $420m in milestones for each product - is aimed at finding new therapies for genetic diseases including cystic fibrosis.

CRISPR Therapeutics was formed by a team led by Emmanuelle Charpentier, who was awarded the Janssen Award for Biomedical Research last year - along with Jennifer Doudna of Editas Medicine - for the discovery of the CRISPR-Cas9 method of gene editing which allows precise alterations to DNA sequences of living cells on demand.

In essence, the technology introduces a break in a specific place within DNA and triggers a self-repair mechanism. However, instead of restoring the original sequence, CRISPR serves as a new template that can be used to modify the sequence.

Vertex' chief scientific officer David Altshuler said that CRISPR-Cas9 is "an important scientific and technological breakthrough that holds significant promise for the future discovery of potentially transformative treatments for many genetic diseases."

The first project in the four-year agreement will look at the possibility of using CRISPR-Cas9 to correct the mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that underpins the disease, as well as other contributing genes.

A second project will take a similar approach in haemoglobinopathies, including and sickle cell disease.

Vertex investment in CRISPR is indicative of the potential of gene-editing, and it follows a number of other deals made by big pharma companies betting that the technique could open up a powerful new therapeutic category.

Celgene has also provided funding to CRISPR Thrapeutics, and earlier this year Novartis entered the fray after signing deals with Caribou Biosciences and Intellia Therapeutics that are focused on the development of CRISPR-based therapeutics, delivered either directly in vivo or ex vivo using modified cells.

Meanwhile, AstraZeneca (AZ) has also played its hand claiming to be leading the field after announcing a CRISPR-focused research collaboration with the Wellcome Trust Sanger Institute, the Innovative Genomics Initiative, ThermoFisher Scientific and the Broad Institute.

Editas - backed by Google and Bill Gates - has yet to announce any collaborations and seems to be intent on developing therapeutics in-house for now.

Article by
Phil Taylor

27th October 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...